Skip to content

Analysis of Contralateral Nerve Symptoms After UBE-LIF Treatment for Lumbar Spondylolisthesis

Analysis of Contralateral Nerve Symptoms After UBE-LIF Treatment for Lumbar Spondylolisthesis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500098593
Enrollment
Unknown
Registered
2025-03-11
Start date
2024-10-01
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar Spondylolisthesis

Interventions

Sponsors

The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients with imaging findings consistent with lumbar spondylolisthesis and corresponding clinical symptoms and signs; 2) All cases involve single-level lesions; 3) Individuals who have not shown improvement or have experienced worsening of symptoms after more than six weeks of conservative treatment; 4) Those with comprehensive preoperative and postoperative clinical and imaging documentation; 5) And those who have been followed up for a minimum of three months postoperatively.

Exclusion criteria

Exclusion criteria: 1) Patients with multilevel lumbar spondylolisthesis; 2) Individuals with a history of previous lumbar spine surgery; 3) Those with severe osteoporosis; 4) Patients with spinal infections; 5) Individuals with secondary hypertension; 6) Patients with diabetes and impaired glucose tolerance; 7) Those with severe impairment of cardiac, pulmonary, liver, or kidney function; 8) Patients with gonadal diseases, adrenal diseases, parathyroid diseases, thyroid diseases, and pituitary disorders; 9) Individuals with a history of immunodeficiency diseases (such as HIV), cancer or malignant tumors, autoimmune diseases, severe cardiovascular or cerebrovascular diseases, or other conditions that may significantly reduce life expectancy; 10) Patients who have participated in any drug clinical trial within the last six months before screening; 11) Patients deemed unsuitable for participation in this study by the researchers.

Design outcomes

Primary

MeasureTime frame
Postoperative foraminal height;

Secondary

MeasureTime frame
Surgical time;Surgical level;Preoperative 3-month lumbar pain VAS score;Postoperative 3-month lumbar pain VAS score;Preoperative 3-month lower extremity pain VAS score;Postoperative 3-month lower extremity pain VAS score;Preoperative 3-month lumbar function JOA score;Postoperative 3-month lumbar function JOA score;Preoperative lumbar lordosis ;Postoperative lumbar lordosis ;Preoperative segmental angle;Postoperative segmental angle;Preoperative anterior disc height;Postoperative anterior disc height;Preoperative posterior disc height;Postoperative posterior disc height;Preoperative foraminal height;Preoperative foraminal width;Postoperative foraminal width;Preoperative foraminal area;Postoperative foraminal area;

Countries

China

Contacts

Public ContactShuncong Zhang

Guangzhou University of Chinese Medicine

1754524849@qq.com+86 198 1194 0894

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026